In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …

Background Interferon-based treatment is not suitable for many patients with hepatitis C
virus (HCV) infection because of contraindications such as psychiatric illness, and a high …

The hepatitis C virus (HCV) was discovered in the late 1980s. Interferon (IFN)-α was
proposed as an antiviral treatment for chronic hepatitis C at about the same time. Successive …

Hepatitis C virus (HCV) infects an estimated 170 million persons worldwide and thus
represents a viral pandemic, one that is five times as widespread as infection with the …

Hepatitis C virus (HCV) is a major cause of liver disease worldwide and a potential cause of
substantial morbidity and mortality in the future. The complexity and uncertainty related to …

The family of interferon (IFN) proteins has now more than reached the potential envisioned
by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical …

Since the identification of the hepatitis C virus, great strides have been made in the
development of an antiviral therapy. As a crucial mediator of the innate antiviral immune …

The treatment of hepatitis C has dramatically improved over the past decade. Unlike any
other chronic viral infection, a significant proportion of patients with chronic hepatitis C can …

Background: Previous studies on the effect of interferon therapy on the incidence of
hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk …